Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$1.06 - $2.33 $36,934 - $81,186
34,844 New
34,844 $37,000
Q3 2021

Nov 15, 2021

SELL
$3.38 - $5.35 $1.21 Million - $1.92 Million
-359,316 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$4.12 - $5.87 $1.21 Million - $1.73 Million
294,743 Added 456.45%
359,316 $1.65 Million
Q1 2021

May 17, 2021

BUY
$3.45 - $9.09 $222,776 - $586,968
64,573 New
64,573 $379,000
Q3 2020

Nov 16, 2020

SELL
$1.44 - $2.1 $656,375 - $957,213
-455,816 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$1.75 - $2.3 $31,325 - $41,170
17,900 Added 4.09%
455,816 $909,000
Q1 2020

May 15, 2020

BUY
$1.8 - $4.28 $266,760 - $634,296
148,200 Added 51.15%
437,916 $854,000
Q4 2019

Feb 14, 2020

BUY
$3.16 - $5.15 $714,476 - $1.16 Million
226,100 Added 355.41%
289,716 $1.2 Million
Q3 2019

Nov 14, 2019

BUY
$1.2 - $6.66 $43,920 - $243,756
36,600 Added 135.48%
63,616 $191,000
Q2 2019

Aug 14, 2019

SELL
$5.35 - $7.11 $52,965 - $70,389
-9,900 Reduced 26.82%
27,016 $170,000
Q1 2019

May 15, 2019

BUY
$4.36 - $7.94 $37,060 - $67,490
8,500 Added 29.91%
36,916 $205,000
Q4 2018

Feb 14, 2019

BUY
$6.15 - $10.51 $78,344 - $133,886
12,739 Added 81.26%
28,416 $189,000
Q3 2018

Nov 14, 2018

SELL
$10.32 - $13.06 $187,824 - $237,692
-18,200 Reduced 53.72%
15,677 $167,000
Q2 2018

Aug 14, 2018

BUY
$7.8 - $13.69 $149,986 - $263,245
19,229 Added 131.27%
33,877 $407,000
Q1 2018

May 15, 2018

BUY
$7.86 - $11.39 $32,005 - $46,380
4,072 Added 38.5%
14,648 $126,000
Q4 2017

Feb 14, 2018

BUY
$8.77 - $12.28 $92,751 - $129,873
10,576
10,576 $104,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $157M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.